lunes, 29 de abril de 2013

Clinical Pharmacology & Therapeutics - Abstract of article: Clinical Implementation of Pharmacogenetics: More than One Gene at a Time

Clinical Pharmacology & Therapeutics - Abstract of article: Clinical Implementation of Pharmacogenetics: More than One Gene at a Time


Commentaries



Clinical Pharmacology & Therapeutics (2013); 93 5, 384–385. doi:10.1038/clpt.2013.7


Clinical Implementation of Pharmacogenetics: More than One Gene at a Time



J A Johnson1, T E Klein2 and M V Relling3



  1. 1Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA

  2. 2Department of Genetics, Stanford University, Stanford, California, USA

  3. 3Pharmaceutical Department, St Jude Children’s Research Hospital, Memphis, Tennessee, USA



Correspondence: J A Johnson, (Johnson@cop.ufl.edu)



Top


Abstract



Tricyclic antidepressant (TCA) clinical pharmacogenetic implementation guidelines for CYP2D6 and CYP2C19 genotypes highlight the importance of both genes. However, studies of the combined impact of the two genes are sparse, limiting the ability to make strong recommendations based on both genes. The warfarin pharmacogenetics literature highlights the strength of a multigenic approach for discovery and clinical implementation. For optimal impact and interpretation, investigators are encouraged to conduct studies in the context of previously well-defined pharmacogenetics markers.


No hay comentarios:

Publicar un comentario